ATS 2024 Final Program

Click on the session title to view the speakers

110

SUNDAY • MAYs 19

911 The MUC5B Genotype and Other Common Variants Are Associated With Computational Imaging Features of Usual Interstitial Pneumonia Pattern Among Patients With Idiopathic Pulmonary Fibrosis 912 The Use of Volatile Organic Compounds as Prognostic Biomarkers in Idiopathic Pulmonary Fibrosis 913 The Potential Lipid Biomarkers 5-HETE for Acute Exacerbations of Idiopathic Pulmonary Fibrosis Identified by Serum Metabolomics 914 Using 129 Xenon MRI to Evaluate the Trajectories of Idiopathic Pulmonary Fibrosis 915 A Monocyte-specific Gene-signature Predicts Outcomes in Patients With Idiopathic Pulmonary Fibrosis and Is Reproducible in Peripheral Blood, Bronchoalveolar Lavage, and Lung Tissue 916 Clinical Utility of MMP7 as a Prognostic Biomarker in Idiopathic Pulmonary Fibrosis 917 Ezetimibe Use and Reduced Mortality in Patients With Idiopathic Pulmonary Fibrosis 919 Interaction of Toll-interacting Protein Single Nucleotide Polymorphism and Antimicrobial Treatment in Idiopathic Pulmonary Fibrosis 920 Mortality and Incidence of Acute Exacerbations in the Era of Anti-Fibrotic Agents in Idiopathic Pulmonary Fibrosis: Preliminary Results of a Multi-Center, Prospective Cohort Study From the Time of Diagnosis 921 Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis 922 Circulating Prostasin: An Independent Risk Marker in Idiopathic Pulmonary Fibrosis (IPF) 923 Lung Involvement in Early Rheumatoid Arthritis, Analysis of the Findra Cohort 924 Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary Fibrosis In Vivo Using Endobronchial Optical Coherence Tomography 925 Nalbuphine Extended-release Reduces Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis

CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

A104 ADVANCES IN THE DIAGNOSIS AND TREATMENT OF ILD 2:15 p.m. - 4:15 p.m. San Diego Convention Center Room 33A-C (Upper Level) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 901 Association of Criteria Defining Progressive Pulmonary Fibrosis With Mortality and Disease Progression 902 Prevalence and Clinical Significance of Pulmonary Progressive Fibrosis in Myositis-associated Interstitial Lung Disease 903 Racial Disparities in Interstitial Lung Disease (ILD): How Race-specific Reference Equations Classify Forced Vital Capacity (FVC) Along the Care Continuum 904 How Community Care CT Reports Compare to Thoracic Radiologist Overread in Identifying Radiographic Features of Fibrosis - A Real-world Cohort Study 905 Disparities in Baseline Lung Function and Pulse Oximetry Correlation at Interstitial Lung Disease Diagnosis Across Racial and Diagnostic Subgroups 906 Racial Differences in Interstitial Lung Abnormalities and Measures of Disease Severity in COPDGene 907 Proteomic Clusters Across the Lung Microenvironment in Idiopathic Pulmonary Fibrosis and Interstitial Pneumonia With Autoimmune Features 908 Multi-site, Real-world Study of the Impact of Rituximab on Physiologic Outcomes for Anti-neutrophil Cytoplasmic Antibody Associated Interstitial Lung Disease 909 Multi-site, Real-world Study of the Impact of Pre-treatment Quantitative Fibrosis Score on Forced Vital Capacity Response for Patients With Rheumatoid Arthritis Interstitial Lung Disease Treated With Immunosuppression 910 Association of Matrix Metalloprotease 12 and Interstitial Lung Disease Diagnosis

ATS 2024 Conference Program • San Diego, CA